9 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
arm of the ongoing I-SPY 2 clinical trial. The study arm targets patients with newly diagnosed estrogen receptor-positive breast cancer whose tumors
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
of the ongoing I-SPY 2 clinical trial. The study arm targets patients with newly diagnosed estrogen receptor-positive breast cancer whose tumors are predicted
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 Nov 23
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:00am
arm targets patients with newly diagnosed estrogen receptor-positive invasive breast cancer whose tumors are predicted to be sensitive to endocrine
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
14 Aug 23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:30am
trial. The study arm targets patients with newly diagnosed estrogen receptor-positive invasive breast cancer whose tumors are predicted to be sensitive
- Prev
- 1
- Next